HealthPhoto: HCPLiveHealthcare Updates: GSK's Bepirovirsen Shows 96-Week Durability in Hepatitis B
This week’s healthcare news highlights GSK’s bepirovirsen demonstrating 96-week durability data in treating hepatitis B. The update provides important insights for healthcare providers on recent breakthroughs and ongoing developments in hepatitis B treatment and other healthcare advancements.
HCPLive·



